BRAF and cancer: Similarly, several studies have demonstrated that cancer cells develop resistance to BRAF inhibitors by overexpressing growth factor receptors at their surface, including KIT, c-MET, EGFR and PDGF-receptor-β (PDFGR-β), leading to MAPK pathway reactivation despite BRAF inhibition (73, 77, 78).